Russell Investments Group Ltd. increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 63.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,361,179 shares of the biopharmaceutical company’s stock after purchasing an additional 912,621 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.18% of Gilead Sciences worth $171,044,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of GILD. Welch Investments LLC acquired a new position in shares of Gilead Sciences during the third quarter worth approximately $108,000. Wealthcare Advisory Partners LLC acquired a new position in shares of Gilead Sciences during the third quarter worth approximately $133,000. Horan Capital Advisors LLC. acquired a new position in shares of Gilead Sciences during the third quarter worth approximately $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of Gilead Sciences during the second quarter worth approximately $147,000. Finally, Hanson & Doremus Investment Management lifted its holdings in shares of Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 1,613 shares during the last quarter. Hedge funds and other institutional investors own 77.83% of the company’s stock.
Shares of Gilead Sciences, Inc. (GILD) opened at $77.18 on Tuesday. Gilead Sciences, Inc. has a 1 year low of $63.76 and a 1 year high of $89.54. The firm has a market capitalization of $104,456.84, a price-to-earnings ratio of 22.18, a price-to-earnings-growth ratio of -1.83 and a beta of 1.24. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.74 and a quick ratio of 2.67.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. The firm had revenue of $5.95 billion for the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business’s revenue was down 18.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.70 earnings per share. equities research analysts anticipate that Gilead Sciences, Inc. will post 6.21 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. This represents a $2.28 annualized dividend and a dividend yield of 2.95%. The ex-dividend date of this dividend is Thursday, March 15th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s dividend payout ratio is presently 65.52%.
A number of brokerages recently commented on GILD. Citigroup upgraded Gilead Sciences from a “neutral” rating to a “buy” rating and cut their target price for the company from $88.80 to $76.00 in a research note on Tuesday, January 30th. Royal Bank of Canada restated a “buy” rating and issued a $94.00 target price on shares of Gilead Sciences in a research note on Friday, February 23rd. BMO Capital Markets upped their target price on Gilead Sciences from $86.00 to $88.00 and gave the company a “market perform” rating in a research note on Thursday, February 8th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price for the company. in a research note on Wednesday, January 17th. Finally, Credit Suisse Group lowered Gilead Sciences from an “outperform” rating to a “neutral” rating and upped their target price for the company from $74.35 to $80.00 in a research note on Wednesday, December 20th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $88.61.
In other news, insider John C. Martin sold 50,000 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $73.62, for a total transaction of $3,681,000.00. Following the sale, the insider now owns 3,046,766 shares in the company, valued at $224,302,912.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $73.87, for a total value of $1,108,050.00. Following the sale, the executive vice president now owns 64,613 shares in the company, valued at approximately $4,772,962.31. The disclosure for this sale can be found here. Insiders have sold 430,268 shares of company stock worth $34,074,395 in the last 90 days. Company insiders own 1.30% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Russell Investments Group Ltd. Has $171.04 Million Position in Gilead Sciences, Inc. (GILD)” was originally reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.thestockobserver.com/2018/03/20/russell-investments-group-ltd-has-171-04-million-position-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.